Physician profile
Clara Chung
NPI 1972575918
$7,092.13
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,430 · 2020: $574 · 2021: $682 · 2022: $609 · 2023: $610 · 2024: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $3,865.92 | 2019-2024 | Xolair |
| Glaxosmithkline, LLC. | $831.99 | 2019-2023 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $664.76 | 2019-2024 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $417.55 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $195.91 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.94 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $139.96 | 2019-2024 | Dupixent |
| Pfizer INC. | $133.73 | 2021-2023 | |
| Grifols USA, LLC | $118.43 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $98.81 | 2019-2021 | |
| Alk-Abello, INC | $98.62 | 2021-2022 | |
| Optinose US, INC. | $73.67 | 2019-2020 | |
| Amgen INC. | $58.11 | 2022-2023 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $51.35 | 2020-2021 | |
| Kaleo, INC. | $48.66 | 2021-2023 | Auvi-Q |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $41.25 | 2019-2020 | |
| Shire North American Group INC | $20.59 | 2019 | |
| Merck Sharp & Dohme LLC | $19.71 | 2021 | |
| Covis Pharma Gmbh | $18.65 | 2019 | |
| Boston Scientific Corporation | $17.31 | 2020 | |
| Eyevance Pharmaceuticals LLC | $13.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clara Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.